Skip to content

Non-surgical Periodontal Treatment With Adjunctive Use of Lactoferrin Contained in Toothpaste and Mouthwash

Non-surgical Periodontal Treatment With Adjunctive Use of Lactoferrin Contained in Toothpaste and Mouthwash: Randomized Clinical Trial

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06311253
Enrollment
40
Registered
2024-03-15
Start date
2024-03-20
Completion date
2025-09-30
Last updated
2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Keywords

pregnant patients

Brief summary

The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients.

Detailed description

The aim of the study is to assess the effect of lactoferrin in LBC complex can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. Patients' enrollment will be conducted according to inclusion criteria. At the first visit, periodontal parameters will be recorded: Plaque Index (PI), recession (R) Bleeding on Probing (BoP), modified Marginal Gingival Index (mMGI), Papillary Marginal Gingival (PMGI), Plaque Control Record ( PCR %), Approximal Plaque Index (API), Clinical Attachment loss (CAL) and Probing Pocket Depth (PPD). Professional debridement will be conducted with piezoelectric instrumentation and air-flow administration with glycine powders. Subsequently, patients will be randomly divided into two groups: \- the Trial group, in which patients will perform home oral hygiene with Emoform Glic toothpaste + mouthwash twice a day the Control group, in which patients will perform home oral hygiene with Emoform Glic toothpaste twice a day. Professional debridement will be repeated every 3 months. Periodontal indexes evaluation will be conducted at the baseline (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3).

Interventions

OTHEREmoform Glic Toothpaste

Daily use of Emoform Glic toothpaste twice a day during home oral hygiene

OTHEREmoform Glic Mouthwash

Daily use of Emoform Glic mouthwash twice a day during home oral hygiene

Sponsors

University of Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* women at the 4th month of pregnancy

Exclusion criteria

* presence of cardiac pacemaker * neurological and psychiatric diseases * patients taking bisphosphonates during the previous 12 months from the - beginning of the study * patients undergoing anticancer therapy. * patients with poor compliance.

Design outcomes

Primary

MeasureTime frameDescription
Change in Recession (R)Baseline, 1, 3 and 6 monthsDistance (in mm) between the gingival margin and the amelo-cemental junction.
Change in Plaque Index (Silness and Loe, 1964)Baseline, 1, 3 and 6 monthsScoring criteria: 0 = no plaque; 1. = thin plaque layer at the gingival margin, only detectable by scraping with a probe; 2. = moderate layer of plaque along the gingival margin; interdental spaces free, but plaque is visible to the naked eye; 3. = abundant plaque along the gingival margin; interdental spaces filled with plaque.
Change in Bleeding on Probing (BoP)Baseline, 1, 3 and 6 monthsSite-specific assessment of the presence or absence of gum bleeding after the insertion of the periodontal probe for the detection of PPD, detected on 6 sites. Percentage of sites with bleeding on probing determines the BOP%.
Change in Probing Pocket Depth (PPD)Baseline, 1, 3 and 6 monthsEvaluation (in mm) of the depth of the gingival sulcus, through a millimeter periodontal probe; it is detected from the gingival margin to the bottom of the gingival sulcus or periodontal pocket, evaluated at 6 sites.
Change in modified Marginal Gingival Index (mMGI)Baseline, 1, 3 and 6 monthsScoring criteria: 0 = Absence of inflammation 1. = Mild inflammation (marginal or papillary unit) 2. = Mild inflammation (entire marginal and papillary unit) 3. = Moderate inflammation 4. = Severe inflammation
Change in Papillary Marginal Gingival Index (PMGI)Baseline, 1, 3 and 6 monthsNumerical score from 0 to 3 of gingival inflammation. Papille and gingival margins (vestibular and lingual) are given a score from 0 to 3. The score is given by the total amount of inflamed sites on the total of examined sites.
Change in Plaque Control Record (PCR%)Baseline, 1, 3 and 6 months% assessment of the amount of plaque on dental surfaces; it is detected on 4 surfaces: distal, mesial, vestibular, lingual / palatal. The number of sites with plaque is divided by the total number of sites available in the mouth and multiplied by 100. Results indicate the index as a percentage.
Change in Clinical Attachment Loss (CAL)Baseline, 1, 3 and 6 monthsMeasurement (in mm) of the position of the gingival margin in relation to the cemento-enamel junction (CEJ).

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026